PLX

#3752
Protalix BioTherapeutics, Inc. Common Stock
2.1250 USD
+0.24%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
2.1150
2.1400
Year Range
2.0300
3.1900
Daily Change
+0.24%
Monthly Change
+0.34%
6 month change
-27.23%
Year Change
-27.23%
Previous Close
2.1200
Open
2.1250
Low
2.1150
High
2.1400
Volume
264
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 171.2147 M
  • Employee 226
  • Founded 1993
  • CEO Dror Bashan
  • Website www.protalix.com
  • Headquarter Delaware, United States
  • FIGI BBG000JW08N5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-22.5
Price to sales ratio
2.68

Protalix BioTherapeutics Inc (DE)

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

News